Fox, Daniel http://orcid.org/0000-0003-0271-2776
Mathur, Anukriti http://orcid.org/0000-0002-7004-301X
Xue, Yansong
Liu, Yunqi
Tan, Wei Hong
Feng, Shouya
Pandey, Abhimanu
Ngo, Chinh
Hayward, Jenni A.
Atmosukarto, Ines I.
Price, Jason D.
Johnson, Matthew D.
Jessberger, Nadja
Robertson, Avril A. B. http://orcid.org/0000-0002-9652-8357
Burgio, Gaetan http://orcid.org/0000-0002-7434-926X
Tscharke, David C. http://orcid.org/0000-0001-6825-9172
Fox, Edward M.
Leyton, Denisse L.
Kaakoush, Nadeem O.
Märtlbauer, Erwin http://orcid.org/0000-0003-3390-8173
Leppla, Stephen H.
Man, Si Ming http://orcid.org/0000-0002-5079-2857
Article History
Received: 3 August 2019
Accepted: 14 January 2020
First Online: 6 February 2020
Competing interests
: I.I.A. declares that they are director of Lipotek, a biotech company focused on liposome technology. I.I.A. and J.D.P. declare that they are shareholders of Lipotek. A.A.B.R. declares that they are a named inventor on inflammasome inhibitor patents (WO2018215818, WO2017140778, and WO2016131098). The other authors declare no competing interests.